Tag: prostate cancer therapeutics market share

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

#Prostate Cancer Therapeutics Market Forecast: Value Set To Climb From $13.95 Billion To $19.25 Billion#_x000D_

The prostate cancer therapeutics market size has demonstrated robust growth over recent years. It is projected to expand from $12.88 billion in 2025 to $13.96 billion in 2026, at a compound annual growth rate (CAGR) of 8.4%. The historical increase in this market can be attributed to several factors, including a rise in prostate cancer incidence, an aging male demographic, innovations in oncology drugs, comprehensive hospital-based cancer care, and increased cancer screening efforts._x000D_

_x000D_

The prostate cancer therapeutics market size is anticipated to expand significantly in the coming years. Its valuation is projected to reach $19.25 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 8.4%. This projected growth can be attributed to factors such as the increasing adoption of precision oncology, the emergence of biomarker-driven therapies, the rise of oral oncology drugs, an expanding immunotherapy pipeline, and growing healthcare expenditure. Important trends for this forecast period encompass the increasing use of targeted therapies, greater utilization of PARP inhibitors, the broader application of immunotherapy in oncology, a shift towards oral cancer medications, and treatment selection guided by precision medicine._x000D_

_x000D_

#Get A Free Sample Report With In-Depth Market Insights:#_x000D_

https://thebusinessresearchcompany.com/sample_request?id=15682264&type=smp&name=Prostate%20Cancer%20Therapeutics%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Prostate Cancer Therapeutics Market Growth Factors: What’s Supporting Expansion?#_x000D_

The prostate cancer therapeutics market is set to expand, driven by the increasing prevalence of prostate cancer. This disease, where malignant cells develop in the prostate gland, primarily affects older males, and its rising occurrence is linked to an aging demographic. The risk of developing prostate cancer significantly increases with age, and longer life expectancies mean more men are living long enough to be affected. Prostate cancer therapeutics aid in managing this condition by targeting cancer cells, slowing disease progression, and enhancing quality of life through various treatments like surgery, radiation, hormone therapy, and newer immunotherapies. For example, in January 2025, Prostate Cancer UK reported an increase in diagnosed cases from 50,751 in 2022 to 55,033 in 2023. Therefore, the growing incidence of prostate cancer is propelling the growth of the prostate cancer therapeutics market._x000D_

_x000D_

#Prostate Cancer Therapeutics Market Segment Breakdown: Which Categories Lead On Revenue?#_x000D_

The prostate cancer therapeutics market covered in this report is segmented – _x000D_

_x000D_

1) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other Therapies_x000D_

2) By Drug Class: Androgen Receptor Inhibitors, GnRH Receptor Antagonists, PARP Inhibitors, Immune Checkpoint Inhibitors, Other Drug Classes_x000D_

3) By Route Of Administration: Oral, Injectable_x000D_

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies_x000D_

5) By End User: Clinics, Hospitals, Other End Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors_x000D_

2) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens_x000D_

3) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines_x000D_

4) By Targeted Therapy: PARP Inhibitors, Radioligand Therapy_x000D_

5) By Other Therapies: Radiotherapy, Bone-Targeted Therapies, Cryotherapy, High-Intensity Focused Ultrasound_x000D_

_x000D_

#Prostate Cancer Therapeutics Market Industry Trends: What’s Reshaping Demand?#_x000D_

Leading companies in the prostate cancer therapeutics market are concentrating on developing innovative treatments, such as a once-daily oral medication for advanced prostate cancer, to enhance patient adherence and improve overall treatment outcomes. This daily oral pill for advanced prostate cancer refers to therapies consumed each day to manage metastatic castration-resistant prostate cancer by inhibiting the effects of testosterone on cancer cells. For example, in January 2024, Zydus Lifesciences, an India-based firm, introduced Rexigo, India’s first oral once-a-day pill containing relugolix for patients with advanced prostate cancer. This convenient and affordable substitute for injectable hormone therapies quickly suppresses testosterone, assisting in controlling cancer growth while offering an improved cardiovascular safety profile. As an oral therapy, it removes the requirement for injectable treatments that necessitate administration by healthcare providers, thus providing greater convenience for patients. This launch signifies a substantial advancement in prostate cancer management in India, offering patients and doctors a new, convenient, safe, and cost-effective treatment alternative._x000D_

_x000D_

#Prostate Cancer Therapeutics Market Leading Players And Competitive Positioning#_x000D_

Major companies operating in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Ferring B.V. _x000D_

_x000D_

#View The Full Prostate Cancer Therapeutics Market Report:#_x000D_

https://thebusinessresearchcompany.com/report/prostate-cancer-therapeutics-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Prostate Cancer Therapeutics Market Regional Breakdown: Where Is Demand Concentrated?#_x000D_

North America was the largest region in the prostate cancer therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Reach Out To Our Team:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas: +1 310-496-7795_x000D_

Asia: +44 7882 955267 & +91 8897263534_x000D_

Europe: +44 7882 955267_x000D_

Email us at: marketing@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Prostate Cancer Therapeutics Market Size Forecast: How Large Could The Market Become By 2030?

The prostate cancer therapeutics market has experienced robust expansion in recent years, with projections indicating an increase from $12.88 billion in 2025 to $13.96 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.4%. This historical growth has been driven by factors such as a higher prevalence of prostate cancer, an aging male demographic, progress in oncology drug development, the provision of cancer care within hospital settings, and a greater emphasis on cancer screening initiatives.

The size of the prostate cancer therapeutics market is anticipated to experience robust expansion over the coming years. By 2030, it is projected to reach $19.25 billion, reflecting a compound annual growth rate (CAGR) of 8.4%. Several factors are driving this forecasted growth, including the adoption of precision oncology, the rise of biomarker-driven therapies, an increase in oral oncology drugs, an expanding immunotherapy pipeline, and higher healthcare spending. Key trends shaping this period encompass a growing preference for targeted therapies, increased utilization of PARP inhibitors, the broader application of immunotherapy in oncology, a transition toward oral cancer medications, and treatment selections guided by precision medicine.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24389&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Prostate Cancer Therapeutics Market Growth Momentum: Which Factors Are Influencing Demand?

The rising prevalence of prostate cancer is anticipated to drive expansion in the prostate cancer therapeutics market moving forward. This disease involves the formation of malignant cells within the prostate gland tissues, predominantly affecting older men. Its growing incidence is linked to an aging population, as the likelihood of developing the condition significantly increases with age, and extended life expectancy allows more men to reach ages where it commonly occurs. Prostate cancer therapeutics are designed to manage the illness by focusing on cancerous cells, decelerating disease progression, and enhancing quality of life through interventions like surgery, radiation, hormone therapy, and emerging options such as immunotherapy. As an example, in January 2025, data from Prostate Cancer UK, a nonprofit cancer research and advocacy organization based in the UK, revealed that diagnosed prostate cancer cases rose from 50,751 in 2022 to 55,033 in 2023. Consequently, the escalating incidence of prostate cancer is fueling growth in the prostate cancer therapeutics market.

Prostate Cancer Therapeutics Market Segment Analysis: What Are The Major Market Categories?

The prostate cancer therapeutics market covered in this report is segmented –

1) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other Therapies

2) By Drug Class: Androgen Receptor Inhibitors, GnRH Receptor Antagonists, PARP Inhibitors, Immune Checkpoint Inhibitors, Other Drug Classes

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

5) By End User: Clinics, Hospitals, Other End Users

Subsegments:

1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors

2) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens

3) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines

4) By Targeted Therapy: PARP Inhibitors, Radioligand Therapy

5) By Other Therapies: Radiotherapy, Bone-Targeted Therapies, Cryotherapy, High-Intensity Focused Ultrasound

Prostate Cancer Therapeutics Market Trends Reshaping Industry Growth

Key players in the prostate cancer therapeutics sector are intensifying efforts to develop innovative treatments like a once-daily oral pill designed for advanced stages of the disease, aiming to boost patient adherence and enhance therapeutic results. This type of medication is taken each day to address metastatic castration-resistant prostate cancer by blocking the effects of testosterone on malignant cells. A notable example occurred in January 2024, when Zydus Lifesciences, a pharmaceutical firm based in India, introduced Rexigo, the country’s first daily oral tablet containing relugolix for those with advanced prostate cancer. This option serves as an accessible and cost-effective substitute for injectable hormone therapies, rapidly reducing testosterone levels to curb tumor progression, while also providing a more favorable cardiovascular risk profile. Since it is taken orally, patients no longer need to visit healthcare professionals for injections, significantly improving convenience. The introduction of this treatment marks a major step forward in managing prostate cancer within India, equipping both patients and physicians with a novel, practical, safer, and economical solution.

Prostate Cancer Therapeutics Market Leading Companies Driving Competitive Growth

Major companies operating in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Ferring B.V.

Access The Complete Prostate Cancer Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-therapeutics-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Prostate Cancer Therapeutics Market Regional Analysis: Which Region Leads By Revenue?

North America was the largest region in the prostate cancer therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Are The Forecasted Market Size Figures For The Prostate Cancer Therapeutics Market In 2026 And 2030?

The prostate cancer therapeutics market size has demonstrated strong growth in recent years. It is projected to expand from $12.88 billion in 2025 to $13.96 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.4%. The historical increase can be attributed to factors such as a rise in prostate cancer incidence, an aging male population, breakthroughs in oncology drugs, readily available hospital-based cancer care, and increased cancer screening efforts.

The prostate cancer therapeutics market size is anticipated to undergo significant expansion over the next few years. It is projected to reach $19.25 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.4%. The impetus for this growth during the forecast period stems from the uptake of precision oncology, the development of biomarker-driven treatments, an increase in oral oncology drugs, a broadening immunotherapy pipeline, and escalating healthcare expenditure. Noteworthy trends for the forecast period involve the increasing embrace of targeted therapies, the rising deployment of PARP inhibitors, the wider application of immunotherapy in cancer treatment, a transition towards oral cancer medications, and treatment selection guided by precision medicine.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24389&type=smp

What Are The Main Drivers Accelerating The Growth Of The Prostate Cancer Therapeutics Market?

The rising occurrence of prostate cancer is anticipated to boost the expansion of the prostate cancer therapeutics market in the future. Prostate cancer is characterized by the formation of malignant cells in the prostate gland, primarily affecting older males. The growing number of prostate cancer cases is linked to an aging global population, given that the likelihood of developing the condition increases substantially with age, and extended life expectancies mean more men reach an age where they are susceptible. Prostate cancer therapeutics assist in managing this condition by targeting cancerous cells, slowing the disease’s advancement, and enhancing the quality of life through various treatments like surgery, radiation, hormone therapy, and modern approaches such as immunotherapy. As an illustration, Prostate Cancer UK reported in January 2025 that the number of men diagnosed with prostate cancer climbed from 50,751 cases in 2022 to 55,033 cases in 2023. Consequently, the heightened incidence of prostate cancer is fueling the growth of the prostate cancer therapeutics market.

What Segment Types Are Included In The Prostate Cancer Therapeutics Market Analysis?

The prostate cancer therapeutics market covered in this report is segmented –

1) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other Therapies

2) By Drug Class: Androgen Receptor Inhibitors, GnRH Receptor Antagonists, PARP Inhibitors, Immune Checkpoint Inhibitors, Other Drug Classes

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

5) By End User: Clinics, Hospitals, Other End Users

Subsegments:

1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors

2) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens

3) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines

4) By Targeted Therapy: PARP Inhibitors, Radioligand Therapy

5) By Other Therapies: Radiotherapy, Bone-Targeted Therapies, Cryotherapy, High-Intensity Focused Ultrasound

Which Trends Are Affecting The Prostate Cancer Therapeutics Market Framework?

Major companies in the prostate cancer therapeutics market are concentrating on developing innovative treatments, such as an oral once-a-day pill designed for advanced prostate cancer, aiming to enhance patient adherence and overall treatment results. This oral once-a-day medication for advanced prostate cancer describes therapies administered daily to manage metastatic castration-resistant prostate cancer by hindering testosterone’s effects on cancer cells. For example, in January 2024, the India-based company Zydus Lifesciences introduced Rexigo, which is India’s initial oral once-a-day pill containing relugolix for individuals with advanced prostate cancer. This convenient and economical substitute for injectable hormone therapies quickly reduces testosterone, assisting in the control of cancer progression while providing a superior cardiovascular safety profile. Being an oral therapy, it removes the necessity for injectable treatments that require administration by healthcare professionals, thereby offering greater convenience for patients. This introduction signifies a major progression in prostate cancer management within India, equipping patients and doctors with a novel, accessible, secure, and cost-efficient treatment choice.

Which Industry Players Are Present In The Prostate Cancer Therapeutics Market?

Major companies operating in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol‑Myers Squibb Company, F. Hoffmann‑La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Ferring B.V.

Access The Complete Prostate Cancer Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-therapeutics-global-market-report

Which Region Is The Dominant Market In The Prostate Cancer Therapeutics Market?

North America was the largest region in the prostate cancer therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Prostate Cancer Therapeutics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24389&type=smp

Browse Through More Reports Similar to the Global Prostate Cancer Therapeutics Market 2026, By The Business Research Company

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Metastatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/metastatic-cancer-drugs-global-market-report

Urothelial Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/urothelial-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Prostate Cancer Therapeutics Market During 2026–2030?

The prostate cancer therapeutics market size has observed substantial growth in recent years. It is projected to expand from $12.88 billion in 2025 to $13.96 billion in 2026, at a compound annual growth rate (CAGR) of 8.4%. The increase during the historical period is attributable to a rising incidence of prostate cancer, an aging male demographic, advancements in oncology drugs, the provision of hospital-based cancer care, and increased cancer screening efforts.

The prostate cancer therapeutics market is anticipated to show significant expansion in the coming years. Its size is projected to reach $19.25 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.4%. This growth during the forecast period is propelled by factors such as the adoption of precision oncology, the emergence of biomarker-driven therapies, the rise in oral oncology drugs, an expanding pipeline of immunotherapies, and increased healthcare expenditure. Notable trends expected in this period involve the increasing uptake of targeted therapies, a rise in the use of PARP inhibitors, the broader application of immunotherapy in oncology, a transition towards oral cancer medications, and treatment selection guided by precision medicine.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24389&type=smp

What Key Factors Are Affecting The Prostate Cancer Therapeutics Market Demand?

The increasing occurrence of prostate cancer is projected to drive the growth of the prostate cancer therapeutics market in the coming years. Prostate cancer is a condition where malignant cells develop within the tissues of the prostate gland, typically impacting older men. The incidence of prostate cancer is rising due to an aging population, as the risk of developing this disease substantially increases with age, and longer life expectancy means more men live long enough to be affected. Prostate cancer therapeutics aid in managing the disease by targeting cancer cells, decelerating its progression, and improving the quality of life through treatments such as surgery, radiation, hormone therapy, and contemporary alternatives like immunotherapy. For instance, in January 2025, according to Prostate Cancer UK, a UK-based nonprofit cancer research and advocacy organization, the number of men diagnosed with prostate cancer rose from 50,751 cases in 2022 to 55,033 cases in 2023. Therefore, the escalating incidence of prostate cancer is stimulating the expansion of the prostate cancer therapeutics market.

What Are The Main Segments Within The Prostate Cancer Therapeutics Market Segment Structure?

The prostate cancer therapeutics market covered in this report is segmented –

1) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other Therapies

2) By Drug Class: Androgen Receptor Inhibitors, GnRH Receptor Antagonists, PARP Inhibitors, Immune Checkpoint Inhibitors, Other Drug Classes

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

5) By End User: Clinics, Hospitals, Other End Users

Subsegments:

1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors

2) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens

3) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines

4) By Targeted Therapy: PARP Inhibitors, Radioligand Therapy

5) By Other Therapies: Radiotherapy, Bone-Targeted Therapies, Cryotherapy, High-Intensity Focused Ultrasound

Which Trends Are Impacting The Progress Of The Prostate Cancer Therapeutics Market?

Leading companies within the prostate cancer therapeutics market are concentrating on developing advanced innovative treatments, such as an oral daily pill for advanced prostate cancer, to improve patient adherence and overall treatment results. This oral once-a-day pill for advanced prostate cancer refers to therapies designed for daily intake to manage metastatic castration-resistant prostate cancer by inhibiting testosterone’s impact on cancer cells. For example, in January 2024, Zydus Lifesciences, an India-based company, launched Rexigo, India’s first oral once-a-day pill containing relugolix for patients with advanced prostate cancer. This convenient and affordable substitute for injectable hormone therapies swiftly lowers testosterone, assisting in the control of cancer growth while also providing an enhanced cardiovascular safety profile. Being an oral therapy, it eliminates the requirement for injectable treatments that necessitate administration by healthcare providers, thus offering greater convenience for patients. This introduction marks a substantial progression in prostate cancer management in India, presenting patients and doctors with a novel, convenient, safe, and cost-effective therapeutic option.

Who Are The Companies Participating In The Prostate Cancer Therapeutics Market?

Major companies operating in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Ferring B.V.

Get The Full Prostate Cancer Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-therapeutics-global-market-report

Which Region Dominates The Prostate Cancer Therapeutics Market By Market Share?

North America was the largest region in the prostate cancer therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Prostate Cancer Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Prostate Cancer Therapeutics Market 2026, By The Business Research Company

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Metastatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/metastatic-cancer-drugs-global-market-report

Urothelial Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/urothelial-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Prostate Cancer Therapeutics Market In 2026 And What Value Is Projected For 2030?

The prostate cancer therapeutics market size has experienced robust growth in recent years. It is projected to expand from $12.88 billion in 2025 to $13.96 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.4%. The historical increase can be attributed to factors such as rising prostate cancer incidence, an aging male population, advancements in oncology drugs, enhanced hospital-based cancer care, and increased cancer screening.

The prostate cancer therapeutics market size is projected to experience robust expansion in the coming years. It is expected to reach $19.25 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.4%. This anticipated growth during the forecast period can be attributed to the adoption of precision oncology, the development of biomarker-driven therapies, an increase in oral oncology drugs, an expanding immunotherapy pipeline, and rising healthcare expenditure. Significant trends for the forecast period include the increasing integration of targeted therapies, a rise in the use of PARP inhibitors, the broader application of immunotherapy in oncology, a shift towards oral cancer medications, and treatment selection based on precision medicine.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24389&type=smp

What Major Drivers Are Influencing Demand In The Prostate Cancer Therapeutics Market?

The rising occurrence of prostate cancer is anticipated to propel the expansion of the prostate cancer therapeutics market moving forward. Prostate cancer is characterized by the development of malignant cells in the prostate gland tissues, typically affecting older men. The increasing rate of prostate cancer diagnoses is attributed to the aging population, as the risk of developing the disease substantially increases with age, and longer life expectancies mean more men live long enough to develop it. Prostate cancer therapeutics assist in managing the condition by targeting cancer cells, slowing progression, and improving patients’ quality of life through treatments such as surgery, radiation, hormone therapy, and newer options like immunotherapy. For instance, according to Prostate Cancer UK, a UK-based nonprofit cancer research and advocacy organization, in January 2025, the number of men diagnosed with prostate cancer rose from 50,751 cases in 2022 to 55,033 cases in 2023. Thus, the growing incidence of prostate cancer is a primary force driving the growth of the prostate cancer therapeutics market.

What Are The Key Segments Of The Prostate Cancer Therapeutics Market?

The prostate cancer therapeutics market covered in this report is segmented –

1) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other Therapies

2) By Drug Class: Androgen Receptor Inhibitors, GnRH Receptor Antagonists, PARP Inhibitors, Immune Checkpoint Inhibitors, Other Drug Classes

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

5) By End User: Clinics, Hospitals, Other End Users

Subsegments:

1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors

2) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens

3) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines

4) By Targeted Therapy: PARP Inhibitors, Radioligand Therapy

5) By Other Therapies: Radiotherapy, Bone-Targeted Therapies, Cryotherapy, High-Intensity Focused Ultrasound

What Key Trends Are Influencing The Development Of The Prostate Cancer Therapeutics Market?

Leading companies in the prostate cancer therapeutics market are concentrating on developing innovative treatments, such as a daily oral pill for advanced prostate cancer, to enhance patient compliance and improve overall treatment outcomes. This oral once-a-day pill for advanced prostate cancer refers to therapies administered daily to manage metastatic castration-resistant prostate cancer by inhibiting testosterone’s effects on cancer cells. For instance, in January 2024, Zydus Lifesciences, an India-based company, introduced Rexigo, India’s first daily oral pill containing relugolix for advanced prostate cancer patients. This convenient and affordable alternative to injectable hormone therapies rapidly suppresses testosterone, helping control cancer growth while offering an improved cardiovascular safety profile. As an oral therapy, it eliminates the need for injectable treatments that require administration by healthcare providers, thus offering greater patient convenience. This launch signifies a substantial advancement in prostate cancer management in India, providing patients and doctors with a new, convenient, safe, and cost-effective treatment option.

Who Are The Leading Companies Operating In The Prostate Cancer Therapeutics Market?

Major companies operating in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Ferring B.V.

Read the full prostate cancer therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-therapeutics-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Prostate Cancer Therapeutics Market?

North America was the largest region in the prostate cancer therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Prostate Cancer Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24389&type=smp

Browse Through More Reports Similar to the Global Prostate Cancer Therapeutics Market 2026, By The Business Research Company

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Metastatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/metastatic-cancer-drugs-global-market-report

Urothelial Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/urothelial-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Prostate Cancer Therapeutics Market In 2026 And What Value Is Projected For 2030?

The prostate cancer therapeutics market size has experienced robust growth in recent years. It is projected to expand from $12.88 billion in 2025 to $13.96 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.4%. The historical increase can be attributed to factors such as rising prostate cancer incidence, an aging male population, advancements in oncology drugs, enhanced hospital-based cancer care, and increased cancer screening.

The prostate cancer therapeutics market size is projected to experience robust expansion in the coming years. It is expected to reach $19.25 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.4%. This anticipated growth during the forecast period can be attributed to the adoption of precision oncology, the development of biomarker-driven therapies, an increase in oral oncology drugs, an expanding immunotherapy pipeline, and rising healthcare expenditure. Significant trends for the forecast period include the increasing integration of targeted therapies, a rise in the use of PARP inhibitors, the broader application of immunotherapy in oncology, a shift towards oral cancer medications, and treatment selection based on precision medicine.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24389&type=smp

What Major Drivers Are Influencing Demand In The Prostate Cancer Therapeutics Market?

The rising occurrence of prostate cancer is anticipated to propel the expansion of the prostate cancer therapeutics market moving forward. Prostate cancer is characterized by the development of malignant cells in the prostate gland tissues, typically affecting older men. The increasing rate of prostate cancer diagnoses is attributed to the aging population, as the risk of developing the disease substantially increases with age, and longer life expectancies mean more men live long enough to develop it. Prostate cancer therapeutics assist in managing the condition by targeting cancer cells, slowing progression, and improving patients’ quality of life through treatments such as surgery, radiation, hormone therapy, and newer options like immunotherapy. For instance, according to Prostate Cancer UK, a UK-based nonprofit cancer research and advocacy organization, in January 2025, the number of men diagnosed with prostate cancer rose from 50,751 cases in 2022 to 55,033 cases in 2023. Thus, the growing incidence of prostate cancer is a primary force driving the growth of the prostate cancer therapeutics market.

What Are The Key Segments Of The Prostate Cancer Therapeutics Market?

The prostate cancer therapeutics market covered in this report is segmented –

1) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other Therapies

2) By Drug Class: Androgen Receptor Inhibitors, GnRH Receptor Antagonists, PARP Inhibitors, Immune Checkpoint Inhibitors, Other Drug Classes

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

5) By End User: Clinics, Hospitals, Other End Users

Subsegments:

1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors

2) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens

3) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines

4) By Targeted Therapy: PARP Inhibitors, Radioligand Therapy

5) By Other Therapies: Radiotherapy, Bone-Targeted Therapies, Cryotherapy, High-Intensity Focused Ultrasound

What Key Trends Are Influencing The Development Of The Prostate Cancer Therapeutics Market?

Leading companies in the prostate cancer therapeutics market are concentrating on developing innovative treatments, such as a daily oral pill for advanced prostate cancer, to enhance patient compliance and improve overall treatment outcomes. This oral once-a-day pill for advanced prostate cancer refers to therapies administered daily to manage metastatic castration-resistant prostate cancer by inhibiting testosterone’s effects on cancer cells. For instance, in January 2024, Zydus Lifesciences, an India-based company, introduced Rexigo, India’s first daily oral pill containing relugolix for advanced prostate cancer patients. This convenient and affordable alternative to injectable hormone therapies rapidly suppresses testosterone, helping control cancer growth while offering an improved cardiovascular safety profile. As an oral therapy, it eliminates the need for injectable treatments that require administration by healthcare providers, thus offering greater patient convenience. This launch signifies a substantial advancement in prostate cancer management in India, providing patients and doctors with a new, convenient, safe, and cost-effective treatment option.

Who Are The Leading Companies Operating In The Prostate Cancer Therapeutics Market?

Major companies operating in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Ferring B.V.

Read the full prostate cancer therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-therapeutics-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Prostate Cancer Therapeutics Market?

North America was the largest region in the prostate cancer therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Prostate Cancer Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24389&type=smp

Browse Through More Reports Similar to the Global Prostate Cancer Therapeutics Market 2026, By The Business Research Company

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Metastatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/metastatic-cancer-drugs-global-market-report

Urothelial Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/urothelial-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Prostate Cancer Therapeutics Market In 2026 And What Value Is Projected For 2030?

The prostate cancer therapeutics market size has experienced robust growth in recent years. It is projected to expand from $12.88 billion in 2025 to $13.96 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.4%. The historical increase can be attributed to factors such as rising prostate cancer incidence, an aging male population, advancements in oncology drugs, enhanced hospital-based cancer care, and increased cancer screening.

The prostate cancer therapeutics market size is projected to experience robust expansion in the coming years. It is expected to reach $19.25 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.4%. This anticipated growth during the forecast period can be attributed to the adoption of precision oncology, the development of biomarker-driven therapies, an increase in oral oncology drugs, an expanding immunotherapy pipeline, and rising healthcare expenditure. Significant trends for the forecast period include the increasing integration of targeted therapies, a rise in the use of PARP inhibitors, the broader application of immunotherapy in oncology, a shift towards oral cancer medications, and treatment selection based on precision medicine.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24389&type=smp

What Major Drivers Are Influencing Demand In The Prostate Cancer Therapeutics Market?

The rising occurrence of prostate cancer is anticipated to propel the expansion of the prostate cancer therapeutics market moving forward. Prostate cancer is characterized by the development of malignant cells in the prostate gland tissues, typically affecting older men. The increasing rate of prostate cancer diagnoses is attributed to the aging population, as the risk of developing the disease substantially increases with age, and longer life expectancies mean more men live long enough to develop it. Prostate cancer therapeutics assist in managing the condition by targeting cancer cells, slowing progression, and improving patients’ quality of life through treatments such as surgery, radiation, hormone therapy, and newer options like immunotherapy. For instance, according to Prostate Cancer UK, a UK-based nonprofit cancer research and advocacy organization, in January 2025, the number of men diagnosed with prostate cancer rose from 50,751 cases in 2022 to 55,033 cases in 2023. Thus, the growing incidence of prostate cancer is a primary force driving the growth of the prostate cancer therapeutics market.

What Are The Key Segments Of The Prostate Cancer Therapeutics Market?

The prostate cancer therapeutics market covered in this report is segmented –

1) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other Therapies

2) By Drug Class: Androgen Receptor Inhibitors, GnRH Receptor Antagonists, PARP Inhibitors, Immune Checkpoint Inhibitors, Other Drug Classes

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

5) By End User: Clinics, Hospitals, Other End Users

Subsegments:

1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors

2) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens

3) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines

4) By Targeted Therapy: PARP Inhibitors, Radioligand Therapy

5) By Other Therapies: Radiotherapy, Bone-Targeted Therapies, Cryotherapy, High-Intensity Focused Ultrasound

What Key Trends Are Influencing The Development Of The Prostate Cancer Therapeutics Market?

Leading companies in the prostate cancer therapeutics market are concentrating on developing innovative treatments, such as a daily oral pill for advanced prostate cancer, to enhance patient compliance and improve overall treatment outcomes. This oral once-a-day pill for advanced prostate cancer refers to therapies administered daily to manage metastatic castration-resistant prostate cancer by inhibiting testosterone’s effects on cancer cells. For instance, in January 2024, Zydus Lifesciences, an India-based company, introduced Rexigo, India’s first daily oral pill containing relugolix for advanced prostate cancer patients. This convenient and affordable alternative to injectable hormone therapies rapidly suppresses testosterone, helping control cancer growth while offering an improved cardiovascular safety profile. As an oral therapy, it eliminates the need for injectable treatments that require administration by healthcare providers, thus offering greater patient convenience. This launch signifies a substantial advancement in prostate cancer management in India, providing patients and doctors with a new, convenient, safe, and cost-effective treatment option.

Who Are The Leading Companies Operating In The Prostate Cancer Therapeutics Market?

Major companies operating in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Ferring B.V.

Read the full prostate cancer therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-therapeutics-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Prostate Cancer Therapeutics Market?

North America was the largest region in the prostate cancer therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Prostate Cancer Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24389&type=smp

Browse Through More Reports Similar to the Global Prostate Cancer Therapeutics Market 2026, By The Business Research Company

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Metastatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/metastatic-cancer-drugs-global-market-report

Urothelial Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/urothelial-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the prostate cancer therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Prostate Cancer Therapeutics Market show for the 2026–2030 period?

The prostate cancer therapeutics market has experienced substantial growth in recent years. It is projected to expand from $12.88 billion in 2025 to $13.96 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 8.4%. This historical growth can be attributed to several factors, including the increasing incidence of prostate cancer, the demographic shift towards an aging male population, continuous advancements in oncology drugs, the widespread availability of hospital-based cancer care, and enhanced cancer screening efforts.

The prostate cancer therapeutics market size is projected to experience substantial expansion in the coming years. This market is forecast to reach $19.25 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.4%. This anticipated growth during the forecast period stems from factors such as the increasing adoption of precision oncology, the rise of biomarker-driven therapies, the proliferation of oral oncology drugs, a broadening immunotherapy pipeline, and escalating healthcare expenditure. Key trends expected during this period involve the heightened adoption of targeted therapies, an increase in the use of PARP inhibitors, the broadening application of immunotherapy in oncology, a transition towards oral cancer medications, and treatment selection based on precision medicine.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24389&type=smp

What Drivers Are Shaping The Development Of The Prostate Cancer Therapeutics Market?

The projected growth of the prostate cancer therapeutics market going forward is expected to be propelled by the increasing incidence of prostate cancer. This disease involves the formation of malignant cells within the prostate gland tissues, typically impacting older men. The rise in prostate cancer cases is attributed to the aging population, given that the risk of developing the condition substantially increases with age, and longer life expectancy results in more men living long enough to be affected. Prostate cancer therapeutics aid in managing the disease by targeting cancer cells, slowing its progression, and enhancing quality of life through treatments such as surgery, radiation, hormone therapy, and newer alternatives like immunotherapy. For instance, in January 2025, according to Prostate Cancer UK, a UK-based nonprofit cancer research and advocacy organization, the number of men diagnosed with prostate cancer rose from 50,751 cases in 2022 to 55,033 cases in 2023. Therefore, the growing incidence of prostate cancer is driving the expansion of the prostate cancer therapeutics market.

What Segment Types Are Examined In The Prostate Cancer Therapeutics Market?

The prostate cancer therapeutics market covered in this report is segmented –

1) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other Therapies

2) By Drug Class: Androgen Receptor Inhibitors, GnRH Receptor Antagonists, PARP Inhibitors, Immune Checkpoint Inhibitors, Other Drug Classes

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

5) By End User: Clinics, Hospitals, Other End Users

Subsegments:

1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors

2) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens

3) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines

4) By Targeted Therapy: PARP Inhibitors, Radioligand Therapy

5) By Other Therapies: Radiotherapy, Bone-Targeted Therapies, Cryotherapy, High-Intensity Focused Ultrasound

How Are New Market Trends Shaping The Landscape Of The Prostate Cancer Therapeutics Market?

Major companies operating in the prostate cancer therapeutics market are focusing on advancing innovative therapeutics, such as an oral once-a-day pill for advanced prostate cancer, to improve patient compliance and overall treatment outcomes. This daily oral medication for advanced prostate cancer functions by inhibiting the effects of testosterone on cancer cells to manage metastatic castration-resistant prostate cancer. For instance, in January 2024, Zydus Lifesciences, an India-based company, launched Rexigo, India’s first oral once-a-day pill containing relugolix for advanced prostate cancer patients. This provides a convenient and affordable option compared to injectable hormone therapies, rapidly suppressing testosterone to help control cancer growth while also offering a superior cardiovascular safety profile. Being an oral therapy, it eliminates the requirement for injectable treatments that necessitate administration by healthcare providers, thereby enhancing patient convenience. This launch signifies a considerable advancement in prostate cancer management in India, offering patients and doctors a new, convenient, safe, and cost-effective treatment alternative.

Who Are The Top-Performing Companies In The Prostate Cancer Therapeutics Market In Recent Years?

Major companies operating in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Ferring B.V.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-therapeutics-global-market-report

Which Region Currently Holds The Largest Share Of The Prostate Cancer Therapeutics Market?

North America was the largest region in the prostate cancer therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Prostate Cancer Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24389&type=smp

Browse Through More Reports Similar to the Global Prostate Cancer Therapeutics Market 2026, By The Business Research Company

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Metastatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/metastatic-cancer-drugs-global-market-report

Urothelial Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/urothelial-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the prostate cancer therapeutics market from 2025–2034 with trusted insights from The Business Research Company

What Is The Predicted Size Of The Prostate Cancer Therapeutics Industry By 2029?

The prostate cancer therapeutics market has shown robust expansion in recent years. Its valuation is set to increase from $11.92 billion in 2024 to $12.88 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.0%. This historical growth can be attributed to the rising global occurrence of prostate cancer, heightened understanding of early cancer screening and diagnostic initiatives, an expanding elderly male population, and a growing call for tailored and specific therapies.

The prostate cancer therapeutics market is anticipated to experience robust expansion over the next few years, with its size projected to reach $17.77 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.4%. This anticipated growth is primarily driven by factors such as increased healthcare expenditure in emerging economies, a surge in investments directed towards oncology drugs, the expanding availability of advanced imaging and diagnostic tools, and a growing adoption of minimally invasive and non-surgical treatment options. Significant trends expected during this period include further advancements in targeted cancer therapies, the integration of precision cancer medicine, the development of technology-driven diagnostic imaging tools, ongoing progress in radioligand-based treatments, and continued innovations in immunotherapy for prostate cancer.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24389&type=smp

What Major Drivers Are Impacting The Prostate Cancer Therapeutics Market?

The rising occurrence of prostate cancer is projected to stimulate the expansion of the prostate cancer therapeutics market in the coming years. Prostate cancer is characterized by the development of malignant cells within the prostate gland’s tissues, primarily impacting elderly males. The growth in prostate cancer cases can be attributed to an aging global demographic, as the likelihood of developing this condition substantially increases with age, and extended life expectancies mean more men reach an age where they are susceptible. Prostate cancer treatments are crucial for managing the illness by targeting cancerous cells, impeding disease progression, and enhancing patients’ quality of life through various interventions, including surgical procedures, radiation therapy, hormonal treatments, and advanced therapies like immunotherapy. For example, data released in October 2024 by the National Health Service, a UK-based government department, indicated that male cancer diagnoses saw an overall increase of 7% in 2022, climbing from 167,917 to 180,877 instances. This particular increase was predominantly fueled by a considerable spike in prostate cancer diagnoses, which surged by over 25% to 54,732 cases. Consequently, the escalating incidence of prostate cancer is a primary driver for the advancement of the prostate cancer therapeutics market.

Which Segment Categories Are Driving Maximum Growth In The Prostate Cancer Therapeutics Market?

The prostate cancer therapeutics market covered in this report is segmented –

1) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other Therapies

2) By Drug Class: Androgen Receptor Inhibitors, GnRH Receptor Antagonists, PARP Inhibitors, Immune Checkpoint Inhibitors, Other Drug Classes

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Sales

5) By End User: Clinics, Hospitals, Other End Users

Subsegments:

1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors

2) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens

3) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines, Cytokine-Based Therapies

4) By Targeted Therapy: PARP Inhibitors, Radioligand Therapy, Tyrosine Kinase Inhibitors

5) By Other Therapies: Radiotherapy, Bone-Targeted Therapies, Cryotherapy, High-Intensity Focused Ultrasound

Which Long-Term Trends Will Play A Crucial Role In The Prostate Cancer Therapeutics Market?

Leading companies in the prostate cancer therapeutics market are concentrating on developing innovative treatments, such as a daily oral pill for advanced prostate cancer, to enhance patient adherence and overall treatment effectiveness. This daily oral pill for advanced prostate cancer refers to therapies administered once a day to manage metastatic castration-resistant prostate cancer by hindering testosterone’s effects on cancer cells. For instance, in January 2024, Zydus Lifesciences, an India-based company, launched Rexigo, which is India’s initial daily oral pill containing relugolix for patients with advanced prostate cancer. This convenient and affordable substitute for injectable hormone therapies quickly suppresses testosterone, aiding in controlling cancer growth while offering an improved cardiovascular safety profile. As an oral therapy, it eliminates the requirement for injectable treatments that necessitate administration by healthcare professionals, thereby providing greater patient convenience. This introduction signifies a major stride in prostate cancer management in India, offering patients and doctors a new, accessible, secure, and cost-effective treatment alternative.

Who Are The Dominant Players In The Prostate Cancer Therapeutics Market Today?

Major companies operating in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Fusion Pharmaceuticals Inc., Ferring B.V., Tolmar Pharmaceuticals Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-therapeutics-global-market-report

Which Region Is At The Forefront Of Innovation In The Prostate Cancer Therapeutics Market?

North America was the largest region in the prostate cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=24389&type=smp

Browse Through More Reports Similar to the Global Prostate Cancer Therapeutics Market 2025, By The Business Research Company

Prostate Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Prostate Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/prostate-cancer-diagnostics-global-market-report

Thyroid Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Prostate Cancer Therapeutics Market By 2029?

The prostate cancer therapeutics market has seen strong growth in recent years. It is anticipated to increase from $11.92 billion in 2024 to $12.88 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.0%. This historical growth can be linked to factors like the rising global occurrence of prostate cancer, increased awareness regarding early cancer screening and diagnosis programs, an expanding elderly male population, and a growing desire for personalized and targeted therapies.

The prostate cancer therapeutics market is projected to experience substantial expansion over the coming years. This market is predicted to reach “$17.77 billion by 2029, achieving a compound annual growth rate (CAGR) of 8.4%. Factors contributing to this growth throughout the forecast period include increasing healthcare spending in developing nations, a surge in investments directed towards oncology medications, broader access to sophisticated imaging and diagnostic equipment, and a greater uptake of less invasive and non-surgical therapeutic approaches. Key trends anticipated during the forecast timeframe encompass improvements in targeted cancer interventions, the incorporation of precision cancer medicine, innovative diagnostic imaging instruments propelled by technology, progress in radioligand-based therapeutic options, and breakthroughs in immunotherapy specifically for prostate cancer.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24389&type=smp

Which Major Market Drivers Are Shaping The Future Of The Prostate Cancer Therapeutics Market?

The increasing occurrence of prostate cancer is anticipated to drive the expansion of the prostate cancer therapeutics market in the future. Prostate cancer is characterized by the formation of malignant cells within the prostate gland’s tissues, typically impacting older men. The rise in prostate cancer cases is attributed to an aging global population, as the likelihood of developing the condition substantially increases with age, and extended life expectancies mean more men live long enough to develop it. Prostate cancer therapeutics assist in managing the disease by targeting cancerous cells, slowing its progression, and enhancing patients’ quality of life through various treatments such as surgery, radiation, hormone therapy, and newer modalities like immunotherapy. For example, in October 2024, the National Health Service, a UK-based government department, reported that overall cancer diagnoses among men saw a 7% increase in 2022, climbing from 167,917 to 180,877 cases. This growth was largely propelled by a significant surge in prostate cancer cases, which escalated by over 25% to 54,732. Thus, the growing incidence of prostate cancer is fueling the growth of the prostate cancer therapeutics market.

Which Key Segments Fueling The Prostate Cancer Therapeutics Market?

The prostate cancer therapeutics market covered in this report is segmented –

1) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other Therapies

2) By Drug Class: Androgen Receptor Inhibitors, GnRH Receptor Antagonists, PARP Inhibitors, Immune Checkpoint Inhibitors, Other Drug Classes

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Sales

5) By End User: Clinics, Hospitals, Other End Users

Subsegments:

1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors

2) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens

3) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines, Cytokine-Based Therapies

4) By Targeted Therapy: PARP Inhibitors, Radioligand Therapy, Tyrosine Kinase Inhibitors

5) By Other Therapies: Radiotherapy, Bone-Targeted Therapies, Cryotherapy, High-Intensity Focused Ultrasound

What Are The Major Trends Driving The Growth Of The Prostate Cancer Therapeutics Market?

Companies operating in the prostate cancer therapeutics market are concentrating on developing innovative treatments, such as an oral once-a-day pill for advanced prostate cancer, to enhance patient adherence and overall therapeutic results. This daily oral medication for advanced prostate cancer involves treatments taken daily to manage metastatic castration-resistant prostate cancer by inhibiting testosterone’s impact on cancer cells. For example, in January 2024, Zydus Lifesciences, an India-based company, launched Rexigo, India’s first oral once-a-day pill containing relugolix, intended for advanced prostate cancer patients. This convenient and affordable alternative to injectable hormone therapies works by rapidly suppressing testosterone, which aids in controlling cancer growth and provides an improved cardiovascular safety profile. As an oral therapy, it removes the requirement for injectable treatments that necessitate administration by healthcare providers, thereby offering greater patient convenience. This launch signifies a substantial progression in prostate cancer management within India, offering patients and doctors a new, convenient, safe, and cost-effective treatment option.

Which Key Market Players Are Investing In Expansion And Innovation Of Prostate Cancer Therapeutics Market?

Major companies operating in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol‑Myers Squibb Company, F. Hoffmann‑La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Fusion Pharmaceuticals Inc., Ferring B.V., Tolmar Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-therapeutics-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Prostate Cancer Therapeutics Market?

North America was the largest region in the prostate cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Prostate Cancer Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24389&type=smp

Browse Through More Reports Similar to the Global Prostate Cancer Therapeutics Market 2025, By The Business Research Company

Prostate Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Prostate Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/prostate-cancer-diagnostics-global-market-report

Thyroid Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model